The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.

This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.

This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.

The invention relates to a method of culturing mammalian cells expressing a heterologous protein in a perfusion cell culture comprising increasing the potassium concentration and decreasing the molar ratio of sodium to potassium to reduce wasteful cell bleed and to increase protein production. The invention further relates to a serum-free perfusion medium comprising a high potassium ion concentration and a low molar ratio of sodium to potassium and to the use of this medium for use in culturing cells in a perfusion culture during production phase or for reducing the cell bleed volume during production phase.

The invention relates to a method of culturing mammalian cells expressing a heterologous protein in a perfusion cell culture comprising increasing the potassium concentration and decreasing the molar ratio of sodium to potassium to reduce wasteful cell bleed and to increase protein production. The invention further relates to a serum-free perfusion medium comprising a high potassium ion concentration and a low molar ratio of sodium to potassium and to the use of this medium for use in culturing cells in a perfusion culture during production phase or for reducing the cell bleed volume during production phase.

The present disclosure provides for non-viral compositions and methods for delivering nucleic acids into eukaryotic cells (e.g., stem cells) with high efficiency and low genotoxicity.

Disclosed herein are systems and methods for manufacturing botulinum neurotoxin serotype E (BoNT/E) with improved yield and purity of BoNT/E. Disclosed herein are systems and methods for manufacturing BoNT/E drug substance.

Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.

The invention is based on the finding that incubating a Cryptosporidium gp40 protein with an aziridine, significantly increases its immunogenicity. When used as a vaccine, this allows a reduction of the dose, which improves economic feasibility and safety. Consequently the aziridine-treated gp40 can now be used as a safe and effective subunit-vaccine for humans or non-human-animals against Cryptosporidiosis. Specifically for new-born ruminants a vaccination by way of colostral transfer was found to be very effective in reducing clinical signs of Cryptosporidiosis, especially diarrhoea.

The invention is based on the finding that incubating a Cryptosporidium gp40 protein with an aziridine, significantly increases its immunogenicity. When used as a vaccine, this allows a reduction of the dose, which improves economic feasibility and safety. Consequently the aziridine-treated gp40 can now be used as a safe and effective subunit-vaccine for humans or non-human-animals against Cryptosporidiosis. Specifically for new-born ruminants a vaccination by way of colostral transfer was found to be very effective in reducing clinical signs of Cryptosporidiosis, especially diarrhoea.